Good distribution and storage practice for injectable medicines in the Philippines: the standards a licensed drug distributor is inspected against

In short: the statute requires an establishment to hold a license before it may handle medicines, but the technical standard behind that license is not in the statute. Department of Health Administrative Order No. 2013-0027 adopts two World Health Organization guides — good distribution practices and good storage practices — as the standard for assessing drug establishments and retailers, and a Food and Drug Administration (FDA) Philippines circular folds compliance with them, including cold chain management where applicable, into the inspection of a drug distributor.

This article is for licensed importers and distributors building or reviewing a quality system, and for hospital pharmacy and procurement staff who want to know what their supplier is measured against. It traces the chain from the statute to the guide an inspector actually opens, and marks each point where we rely on a secondary description rather than a text we could read. Note that License to Operate (LTO) shares its initials with the Land Transportation Office. Nothing below is legal advice, and current orders and forms should be confirmed with the FDA before any filing.

Where the standard actually comes from

Republic Act No. 3720, as amended by Republic Act No. 9711, separates two acts of approval: licensing is the approval of an establishment before it engages in regulated activities, registration the approval of a product before it is marketed. We set out the division of work between the two documents in our article on the License to Operate and the Certificate of Product Registration.

What the statute does not do is describe a warehouse. That content came later. On October 2, 2013 the Department of Health issued Administrative Order No. 2013-0027, "Adoption and Implementation of the World Health Organization Annex 5 Guide to Good Distribution Practices (GDP) for Pharmaceutical Products, and Annex 9 Guide to Good Storage Practices for Pharmaceuticals". Its rationale records that the existing issuances of the authority fell short of that guidance.

The order is short and consequential. Its general guidelines adopt "the current version" of the two guides as supplementary to existing regulations. Its scope reaches the FDA itself and all drug establishments and retailers. Its specific guidelines provide for the adoption of later supplements, for use of the guides as the inspection standard and for revision of the inspection forms, and establishments were given a one-year transition period. So the answer to "which good distribution practice applies here" is not a Philippine manual. It is a World Health Organization text, adopted by reference, with a national transition clause around it.

The World Health Organization text has since been consolidated

This is worth checking before a quality manual is written against a document title. The two guides named in the 2013 order are separate publications: good storage practices appeared in 2003 as Annex 9 of Technical Report Series No. 908, and good distribution practices in 2010 as Annex 5 of Technical Report Series No. 957. In June 2020 the World Health Organization published a single consolidated guideline covering both subjects, "Good storage and distribution practices for medical products", as Annex 7 of Technical Report Series No. 1025.

The consolidated text does not announce itself as a repeal. Its introduction says every activity in storage and distribution should follow the principles of good manufacturing practices, good storage practices and good distribution practices "as applicable", and it cites the 2003 and 2010 annexes among its own references rather than describing them as withdrawn. We found no Philippine issuance naming the 2020 text, while the 2013 order names the two older guides and speaks of their current version and future supplements.

The practical reading for a distributor is therefore conservative. Build the quality system on the material the national order names, keep the 2020 consolidated guideline beside it because that is where the same requirements are now maintained, and ask the FDA which version the inspection form follows. In either case the chapter list of the 2020 annex makes a serviceable table of contents for a quality manual.

Storage conditions and what the label has to say

The 2020 annex ties storage to the label rather than to a house rule: storage conditions should comply with the labeling and the information provided by the manufacturer. Around that sentence sit the obligations inspections tend to turn on. Heating, ventilation and air conditioning systems should be designed, installed, qualified and maintained so that the required conditions hold. Mapping studies for temperature, and for relative humidity where appropriate, should be done in storage areas, refrigerators and freezers. Conditions should be monitored at regular intervals, the data recorded and the records reviewed, and the monitoring equipment should be calibrated and suitable for its intended use. Stock should be rotated on the first expired, first out principle and checked at intervals for items approaching their retest or expiry date.

The annex also tells manufacturers to be exact on the label: descriptions such as "store at ambient conditions" should be avoided and actual limits specified where possible, such as "store below 25 °C". The limits it attaches to the common label phrases are reproduced below. They are recommended values based on pharmacopoeia limits and guidelines, not a substitute for the approved label of a given product.

For parenteral micronutrient formulations the last two rows are rarely decorative. Several compounds used in such preparations are sensitive to light or to oxidation, which is why the primary container and its carton belong to the specification rather than to packaging. Background on individual compounds is in the Knowledge Base entries for ascorbate and the B-complex vitamins.

The cold chain layer

Cold chain obligations arrive through the licensing circulars rather than through the 2013 order. FDA Circular No. 2014-026 of November 21, 2014, implementing Administrative Order No. 2014-0034 on the licensing of drug distributors, requires a pre-opening inspection that determines compliance with the existing guidelines on good distribution and storage practices "including cold-chain management (where applicable)", and states that compliance with cold chain management is also required for drug distributors carrying vaccines, biologics and other temperature-sensitive products.

The authority revisited the subject in Circular No. 2021-003, "Revised Guidelines on the Cold Chain Management for Pharmaceutical Products and Establishments". We could not retrieve that circular, because the FDA pages for circulars and advisories return an access error to our tools. Published descriptions, which we mark as a secondary source, say it covers accuracy checks on temperature control and monitoring devices, qualification of refrigerated road vehicles and of shipping containers, temperature-controlled transport by road and by air, transport route profiling and monitoring systems for transport. Any establishment relying on those requirements should obtain the circular itself from the FDA.

The World Health Organization text behind them is explicit on the two points most often missed in transport. Vehicles should be qualified, where applicable, to demonstrate their capability to maintain the required transport conditions, with a maintenance program for the cooling and heating system; and the instruments monitoring conditions inside vehicles and containers should be calibrated at regular intervals, with records kept and made available for inspection.

What an inspection asks for

Circular No. 2014-026 is the clearest published picture of what a drug distributor shows an inspector, and it notes that establishments already holding an approved LTO face routine inspection under the same provisions. Later orders have changed the licensing framework, so read the list below as subject matter, not as the current form.

That last row is a small but telling requirement: the guides are not only the inspector's yardstick, they are expected on the distributor's shelf. The FDA has also published for comment a guidance classifying inspection findings at drug distributors, drugstores and hospital pharmacies as critical, major or other, with critical findings described as neither appealable nor reclassifiable. We could not read that document either, and it was posted as a draft, so its status should be verified first.

What the manufacturer contributes

Three of the items above originate outside the country. The distributorship agreement needs the manufacturer as counterparty and consular authentication afterwards. The good manufacturing practice document comes from the regulatory authority that supervises the site of manufacture. And the label, which the storage rules point back to, is drafted by the manufacturer and adapted with the local applicant.

The label is also where a Philippine rule that surprises foreign manufacturers applies. Section 6 of Republic Act No. 6675, the Generics Act of 1988, requires those who manufacture, import, repack, market or distribute medicines to indicate the generic name prominently, and on a branded product the generic name belongs immediately above the brand name, in promotional material as well as on the label. Our catalogue entries follow that order: generic name, then brand and presentation.

EFBA is a manufacturer of IV vitamin and nutrient formulations; the manufacturer page describes how they are produced and documented. IVIXIR is not registered; it is not promoted in the Philippines. EFBA provides manufacturer documentation to a licensed local company, which holds the license and files any application in its own name. EFBA does not file applications and does not hold any Philippine license. LTO holders interested in a registration partnership can write through the distributor page.

Records, traceability and recall readiness

A quality system is judged on paper as much as on shelving. The 2020 annex asks for records of all receipts, storage, issues and distribution, listing the date, the product, the quantity, the name and address of supplier and customer, batch numbers, expiry date and the qualification of both parties. Containers should be labeled with at least the product name, batch number, expiry or retest date and the specified storage conditions. On receipt, deliveries should be examined for damage, seal intactness, signs of tampering, labeling and completeness of the order, including the certificate of analysis where applicable; consignments that fail should be kept apart and investigated, which is also the route for a suspected falsified product.

Recall readiness is what those records exist for. The annex asks for a written recall procedure reviewed annually, distribution records detailed enough to permit a recall, prompt notice to the manufacturer or marketing authorization holder and to the regulatory authority, segregation of recalled stock, notice to every customer who may have received the product, and a final report reconciling delivered against recovered quantities. Self-inspection turns the same discipline inward: internal inspections on an annual schedule by people free from bias, recorded in reports that reach management, with corrective and preventive actions reviewed within a defined timeframe. A buyer can ask for the last self-inspection report, which is where our supplier verification checklist picks the subject up.

What we could and could not read

We read Administrative Order No. 2013-0027 and FDA Circular No. 2014-026 in the copies published by the Supreme Court E-Library, and Annex 7 of World Health Organization Technical Report Series No. 1025 in the copy published by the World Health Organization. We did not read Circular No. 2021-003 or the draft guidance on deficiencies, because the FDA pages hosting them are not retrievable by our tools; those passages are marked as secondary above. Administrative Order No. 2020-0017 on licensing is published as a scanned image our tools could not convert to text. The FDA remains the authority on every point.